Abstract
Abstract Developing optimal drug combinations is one of the central challenges of cancer treatment research: drug combinations are used to treat most types of cancer, and are almost exclusively responsible for cures of advanced cancers. However, historically successful combination therapies were developed empirically, and the mechanistic basis for their efficacy has been largely speculative. I will present experiments, models, and computational analyses of clinical trial data, to investigate the mechanistic basis of clinically successful combination therapies across 12 types of cancer and 30 different therapies. These studies consistently identify the control of cancer heterogeneity between-patients (inter-tumor) and within-patients (intra-tumor) by independently active drugs as critical contributors to the efficacy of combination therapies in human patients. The key approaches for data analysis and modeling in these studies consist of adapting classical pharmacological concepts to the complex situation of populations of cancers with heterogeneous drug sensitivity. Synergistic drug interactions in humans appears uncommon among approved combination therapies, and even curative regimens exhibit drug additivity in experimental measurements and in clinical outcomes. Mathematical descriptions of heterogeneity in cellular or patient populations, and quantitative experimental measurements of how drug combinations address heterogeneity, lead to accurate predictions of clinical trial results for a diverse range of combination therapies, including those with immune checkpoint inhibitors (correlation between observed and expected Progression Free Survival in 14 trials, Pearson r = 0.98, P < 10^-8) and curative chemotherapy regimens for hematological cancers (correlation between observed and expected response rates and cure rates in 40 years of trials in childhood ALL, Pearson r = 0.99, P < 10^-10). These results have broad significance for the treatment of cancers, for the interpretation of clinical trials, and point to new opportunities to use combination therapies with greater precision. Citation Format: Adam C. Palmer, Ben Izar, Haeun Hwangbo, Peter K. Sorger. Control of inter- and intra-patient cancer heterogeneity is a predictively accurate explanation for the success of many combination therapies for solid and hematological cancers [abstract]. In: Proceedings of the AACR Virtual Special Conference on Tumor Heterogeneity: From Single Cells to Clinical Impact; 2020 Sep 17-18. Philadelphia (PA): AACR; Cancer Res 2020;80(21 Suppl):Abstract nr PO-072.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.